<DOC>
	<DOCNO>NCT01102426</DOCNO>
	<brief_summary>Study Plitidepsin combination dexamethasone versus dexamethasone alone patient relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Aplidin - Dexamethasone Relapsed/Refractory Myeloma</brief_title>
	<detailed_description>Phase III Study Patients Relapsed/Refractory Multiple Myeloma compare efficacy plitidepsin combination dexamethasone vs. dexamethasone alone measure progression-free survival ( PFS ) evaluate tumor response , duration response ( DR ) , overall survival ( OS ) rule effect plitidepsin duration QT/QTc interval ( time correspond begin depolarization re-polarization ventricle ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 18 year . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 2 Life expectancy ≥ 3 month . Patients previously diagnose multiple myeloma Patients must relapse relapsed refractory multiple myeloma ( MM ) least three six prior therapeutic regimen MM , include induction therapy stem cell transplant candidate patient , consider one regimen . Patients must receive previous bortezomibcontaining lenalidomidecontaining regimen ( thalidomide lenalidomide available ) Women must negative serum pregnancy test Voluntarily sign date write informed consent Concomitant diseases/conditions Women pregnant breast feeding . Concomitant medication include corticosteroid , chemotherapy , therapy may active MM Known hypersensitivity involve study drug formulation component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Aplidin</keyword>
	<keyword>plitidepsin</keyword>
	<keyword>dexamethasone</keyword>
</DOC>